A Safety and Pharmacokinetic Study of 100 mg, 150 mg and 200 mg of Proellex® Taken for Seven Days by Healthy Adult Female Subjects

Trial Profile

A Safety and Pharmacokinetic Study of 100 mg, 150 mg and 200 mg of Proellex® Taken for Seven Days by Healthy Adult Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Telapristone (Primary)
  • Indications Endometriosis; Uterine leiomyoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 11 Feb 2010 Actual number of patients (18) added as reported by ClinicalTrials.gov.
    • 31 Oct 2008 Added October 2008 as the actual completion date, based on information from ClinicalTrials.gov.
    • 13 May 2008 Status changed from recruiting to completed, as reported by Repros Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top